Introduction
============

Internal control genes or housekeeping genes are important in obtaining reliable and reproducible data from gene expression studies in cancer ([@ref-8]). Internal control genes should be abundantly and uniformly expressed across tumor and normal tissues and across different experimental conditions ([@ref-12]). Cancers of head and neck region is the sixth most common cancer worldwide with an incidence of 550,000 cases annually ([@ref-9]). Past studies argue the lack of uniformity of expression on internal control genes based on experimental conditions ([@ref-6]; [@ref-11]). Although there are previous reports that describe the reference or internal control genes in head and neck squamous cell carcinoma (HNSCC) gene expression studies ([@ref-16]), use of high-throughput data like microarrays and RNA-seq from tumors and their matched normal tissues following a confirmation of expression in independent set of samples are scant in the literature. Additionally, it is crucial that the expression of internal control genes remains unaltered across temporal, spatial and experimental conditions that takes into account of the genes with a wide dynamic range of expression. Therefore, revisiting the validity of widely used genes like *ACTB*, *TUBB*, and *GAPDH* is required along with discovery of a minimal set of internal control genes in HNSCC gene expression studies that use expression data from patient cohorts from different geography ([@ref-15], [@ref-14]) and large consortia like TCGA ([@ref-25]).

In the present study, we analyzed HNSCC gene expression data from three sources; *in house* microarray data ([@ref-15], [@ref-14]) (*n* = 21), TCGA RNA-seq data ([@ref-25]) (*n* = 42) and quantitative real-time PCR (qPCR) data on individual genes from the previously published studies ([@ref-2]; [@ref-8]; [@ref-16]; [@ref-17]; [@ref-26]); to come up with a set of genes (discovery set) that are stably and robustly expressed with least variance across tumor:normal pairs. We subsequently validated the expression of the discovery set in additional tumor:normal pairs (*n* = 14) using qPCR and obtained a minimal set of two housekeeping genes by comparing and ranking their expression during validation.

Materials and Methods
=====================

Microarray data processing
--------------------------

The gene expression profiling using Illumina HumanHT-12 v4 expression BeadChips (Illumina, San Diego, CA, USA), raw data collection and data processing using the R package lumi ([@ref-7]) and individual batch-correction using ComBat ([@ref-13]) is described previously ([@ref-15], [@ref-14]). The raw signal intensities from arrays were exported from GenomeStudio for pre-processing and analyzed using *R*. Gene-wise expression intensities for tumor and matched control samples from GenomeStudio were transformed and normalized using variance stabilizing transformation (VST) and LOESS methods, respectively, using lumi ([@ref-7]) and top genes with least across-sample variance in expression were selected. Genes with fold change between 0.95 and 1.05 (tumor/normal) and with standard deviation \< 0.05 for the fold changes were selected further from a larger gene list at a high level in both the microarray and the RNA-seq data ([Table S1](#supp-5){ref-type="supplementary-material"}).

RNA-seq data processing
-----------------------

RSEM-processed RNA-Seq gene expression values (TCGA pipeline, Level 3) were downloaded from the old TCGA repository (<https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/>). The transcripts per kilobase million (TPM) values for all the genes were extracted from the Level 3 files. Further, genes that showed zero or NA values in any of these samples were eliminated, and the log fold change values between the respective tumor and normal samples calculated by taking a log transformation of the ratios between expression values for tumor and normal. We filtered expression data that fulfilled three criteria for all samples; expressed at ≥ 3 TPM, tumor/normal ratio: 0.9--1.1 and standard deviation across all the tissues \< 0.5. Finally genes were short-listed from a larger gene list expressed at a high level in both the microarray and the RNA-seq data ([Table S1](#supp-5){ref-type="supplementary-material"}) for the discovery set.

Discovery set
-------------

In addition to the microarray and RNA-seq gene expression data, the most commonly used internal control genes form the HNSCC gene expression literature ([@ref-2]; [@ref-8]; [@ref-16]; [@ref-17]; [@ref-26]) were also considered to select the discovery set (*n* = 18) ([Table S2](#supp-6){ref-type="supplementary-material"}). These genes were used for validation in an independent set of tumor:normal pairs (*n* = 14) using qPCR.

Patient samples
---------------

Patients were accumulated voluntarily after obtaining informed consent from each patient and as per the guidelines from the institutional ethics committee of the Mazumadar-Shaw Cancer Centre (IRB Approval number: NHH/MEC-CL/2014/197). All the tissues were frozen immediately in liquid nitrogen and stored at −80 °C until further use. Only those tumors with squamous cell carcinoma (with at least 70% tumor cells and with confirmed diagnosis) and their adjacent normal tissues as confirmed by histology ([Fig. S1](#supp-1){ref-type="supplementary-material"}) were included in the current study. Patients underwent staging according to AJCC criteria, and curative intent treatment as per NCCN guidelines involving surgery with or without post-operative adjuvant radiation or chemo-radiation at the Mazumdar Shaw Cancer Centre were accrued for the validation study.

RNA extraction and cDNA synthesis
---------------------------------

The total RNA was extracted from 25 mg of tissues using the RNeasy mini kit (cat:74104; Qiagen, Germantown, MD, USA) with on-column digestion of DNA using RNase free DNase set (cat:79254; Qiagen, Germantown, MD, USA) as per manufacturer's instructions. The RNA quality was checked using gel electrophoresis and Agilent Bioanalyzer. A total of 500 nanogram of total RNA was subjected to cDNA synthesis using Takara's Prime Script first strand cDNA synthesis kit (cat: 6110A).

Quantitative real-time PCR
--------------------------

Quantitative real-time PCR was carried out using KAPA Biosystem's SYBR Fast qPCR universal master mix (cat: KK4601). The primer sequences for all the 18 discovery set reference genes and the amplification conditions are mentioned in [Table 1A](#table-1){ref-type="table"}. The primers were either designed for this study or were chosen from the literature ([@ref-5]) or from the online resources (<https://primerdepot.nci.nih.gov/> and <https://pga.mgh.harvard.edu/primerbank/>). All amplification reactions were carried out in triplicates using three negative controls: no template control with nuclease free water (cat: AM9932; Ambion, Austin, TX, USA), no amplification control and no primer control in each amplification plate. We have followed the guidelines for qPCR experiments as suggested previously ([@ref-3]).
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###### Primers used in the current study (A).
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  A                                                                                                                                  
  ---- ------------------------- --- ------------------------- ------------------------------------------------------ ---- --- ----- -------------------------------------------
  1    *RPL27*                   F   ACAATCACCTAATGCCCACA      [chr17:43000081-43002884](chr17:43000081-43002884)     √    √   146   This study
  R    GCCTGTCTTGTATCTCTCTTCAA                                                                                                       
  2    *RPS29*                   F   GCACTGCTGAGAGCAAGATG      [chr14:49577820-49586363](chr14:49577820-49586363)     √    √   213   [@ref-6]
  R    ATAGGCAGTGCCAAGGAAGA                                                                                                          
  3    *OAZ1*                    F   GGATCCTCAATAGCCACTGC      [chr19:2269621-2271410](chr19:2269621-2271410)         --   √   150   [@ref-6]
  R    TACAGCAGTGGAGGGAGACC                                                                                                          
  4    *RPL30*                   F   ACAGCATGCGGAAAATACTAC     [chr8:98041745-98042696](chr8:98041745-98042696)       --   √   158   [@ref-6]
  R    AAAGGAAAATTTTGCAGGTTT                                                                                                         
  5    *LDHA*                    F   TTGTTGGGGTTGGTGCTGTT      [chr11:18396916-18399514](chr11:18396916-18399514)     --   √   137   This study
  R    AAGGCTGCCATGTTGGAGAT                                                                                                          
  6    *ACTB*                    F   CCTTGCACATGCCGGAG         [chr7:5529603-5530574](chr7:5529603-5530574)           --   √   112   <https://primerdepot.nci.nih.gov>
  R    GCACAGAGCCTCGCCTT                                                                                                             
  7    *RPS13*                   F   CGTCCCCACTTGGTTGAAGTT     [chr11:17075584-17077438](chr11:17075584-17077438)     √    √   129   This study
  R    CGTACTTGTGCAACACCATGT                                                                                                         
  8    *GAPDH*                   F   GCATCCTGGGCTACACTGA       [chr12:6537873-6538138](chr12:6537873-6538138)         --   √   162   [@ref-5]
  R    CCACCACCCTGTTGCTGTA                                                                                                           
  9    *TUBA1B*                  F   GTCGCCTTCGCCTCCTAATC      [chr12:49129610-49131330](chr12:49129610-49131330)     --   √   146   This study
  R    TCACTTGGCATCTGGCCATC                                                                                                          
  10   *PSMC5*                   F   TTGACGGACCAGAGCAGATG      [chr17:63827498-63829528](chr17:63827498-63829528)     √    √   124   This study
  R    CTCCGGAGGTTTTGGCTCTT                                                                                                          
  11   *MTCH1*                   F   CTTGGCGTAGGTGAAGAAGC      [chr6:36978607-36985885](chr6:36978607-36985885)       √    √   123   <https://primerdepot.nci.nih.gov>
  R    CATCCCCTGCTCTACGTGAA                                                                                                          
  12   *MKRN1*                   F   GCAGCAAGGGATGACTTTGT      [chr7:140459862-140471905](chr7:140459862-140471905)   --   √   98    <https://primerdepot.nci.nih.gov>
  R    TGTATTTATGGAGACCGCTGC                                                                                                         
  13   *ERGIC3*                  F   TCTCATGCTGCTACTGTTCCT     [chr20:35542342-35542833](chr20:35542342-35542833)     √    √   152   <https://pga.mgh.harvard.edu/primerbank/>
  R    CAATACTCAGATAGGCACAAGGC                                                                                                       
  14   *ADRM1*                   F   CAATGCTCCTCATCCTGGTC      [chr20:62304519-62306228](chr20:62304519-62306228)     --   √   91    <https://primerdepot.nci.nih.gov>
  R    GGAGGGTCTACGTGCTGAAG                                                                                                          
  15   *RPL37A*                  F   TTCTGATGGCGGACTTTACC      [chr2:216499955-216501378](chr2:216499955-216501378)   --   √   115   <https://primerdepot.nci.nih.gov>
  R    ATGAAGAGACGAGCTGTGGG                                                                                                          
  16   *RPL5*                    F   TCGTATAGCAGCATGAGCTTTC    [chr1:92837537-92840589](chr1:92837537-92840589)       --   √   136   <https://primerdepot.nci.nih.gov>
  R    TGTTGCAGATTACATGCGCT                                                                                                          
  17   *TSPAN31*                 F   GGCTATTAACCGAAGCAAACAGA   [chr12:57746235-57746683](chr12:57746235-57746683)     --   √   117   <https://pga.mgh.harvard.edu/primerbank/>
  R    GTGAGGTTGAATAAGCCACAACA                                                                                                       
  18   *DARS*                    F   AGCCGCAAGAGTCAGGAGA       [chr2:135979349-135985450](chr2:135979349-135985450)   --   √   124   <https://pga.mgh.harvard.edu/primerbank/>
  R    CCCGAACCAAAACTCGATCTG                                                                                                         

  B                                                                                       
  --- --------- ------- ----------- ------- ---------- ------ --------- ------- --------- ------
  1   *RPL30*   0.254   *PSMC5*     0.004   *RPL27*    1.13   *RPL27*   0.278   *RPL30*   1.32
  2   *RPL27*   0.254   *MTCH1*     0.005   *RPS13*    0.90   *RPL30*   0.321   *RPL27*   1.57
  3   *PSMC5*   0.348   *TSPAN21*   0.006   *RPL30*    1.21   *RPL5*    0.362   *PSMC5*   3.35
  4   *OAZ1*    0.365   *DARS*      0.006   *RPL5*     0.82   *RPS13*   0.391   *OAZ1*    5.03
  5   *MKRN1*   0.375   *RPL30*     0.007   *RPL37A*   0.76   *MTCH1*   0.419   *MTCH1*   5.38

**Note:**

Results from different tools on the internal control genes and their ranks as obtained using the validation samples (B).

Statistical analysis
--------------------

For stability comparison of the internal candidate reference genes obtained using the discovery set, we analyzed the validation data independently using four most commonly used algorithms, Genorm ([@ref-26]), Normfinder ([@ref-1]), Bestkeeper ([@ref-19]), and Comparative Ct ([@ref-22]). In addition to the comparative Ct method, we also calculated the values of mean standard deviation ([@ref-24]) of Ct for each gene. The results from the above tools were compared with an online tool Reffinder ([@ref-27]) and the results were interpreted and presented separately. Graphpad prism software version 5 was used to analyze the data and plot the graphs.

Results and Discussion
======================

The schema for selecting genes for discovery set is depicted in [Fig. 1](#fig-1){ref-type="fig"}. After analyzing data from all sources, 18 genes were selected that had least variance across all the tumor and normal samples, were well annotated and had some biology known ([Table 1A](#table-1){ref-type="table"}; [Table S2](#supp-6){ref-type="supplementary-material"}). Standard curves reflecting the linear regression (*R*^2^ \> 0.9) and amplification efficiency ([Fig. S2](#supp-2){ref-type="supplementary-material"}; [Table S3](#supp-7){ref-type="supplementary-material"}) were generated for the select candidate genes. Primers for all the genes showed specific amplifications as shown by the dissociation curves ([Fig. S3](#supp-3){ref-type="supplementary-material"}) and by gel electrophoresis of the amplified products ([Fig. S4](#supp-4){ref-type="supplementary-material"}). Data from qPCR validation of genes ([Fig. 2A](#fig-2){ref-type="fig"}; [Table S3](#supp-7){ref-type="supplementary-material"}) showed variable levels of expression for the 18 genes in different validation samples. As [Fig. 2B](#fig-2){ref-type="fig"} indicates independent results from the four different algorithms (Genorm, Normfinder, Bestkeeper, and Comparative Ct) and the online tool RefFinder. As the tool RefFinder does not take amplification efficiency into account and merely sums up results from other tools, we did not rely on the results from RefFinder but used it as one of the tools along with the other four to interpret the results independently. Out of the 18 genes across all the samples, we ranked the expression of top 11 stably expressed genes namely, *RPL30*, *RPL27*, *PSMC5*, *OAZ1*, *MTCH1*, *TSPAN21*, *DARS*, *MKRN1*, *RPS13*, *RPL5*, and *RPL37A*. Although, there was some inconsistency between the top-ranked genes among the different algorithms/tools, for the genes *RPL27* and *RPL30* the data was consistent across all the algorithms. As both of *RPL27* and *RPL30* belong to the same ribosomal family proteins, and in order to avoid any potential error due to mutual expression alterations of those genes, we considered inclusion of the next three genes *PSMC5*, *MTCH1*, and *OAZ1*, the expression of which were stable across all the samples. Therefore, *RPL27* or *RPL30* in combination with any one of the three *(PSMC5/MTCH1/OAZ1)* fulfilled all the three criteria for ideal internal control genes, least variance across samples, high-level of expression in both tumors and normal and at the top of the rank by the algorithms tested.

![Schema indicating the selection criteria and validation of the internal control genes.](peerj-06-5207-g001){#fig-1}

![Expression of genes in the discovery set across tumors and normal samples.\
(A) The Ct values were generated from qPCR experiments and plotted as box plots with median values as lines and boxes indicating 10--90 percentile values and whiskers as the maximum and minimum values. Ranking of 18 genes using different tools (B). *Y*-axis for different tools represents: stability value (Genorm, Normfinder), standard deviation ± (CP) (Bestkeeper), 2^−(deltaCt)^ (Comparative Ct method) and geomean of ranking (RefFinder). The columns in light grey represent stable genes across tumors and normal samples.](peerj-06-5207-g002){#fig-2}

The aim of the current study was not to select a set of genes for a particular tumor stage and/or differentiation and in response to drug treatment but to select genes that are robustly expressed across multiple tumor stages and differentiation and across tumor and their matched normal samples. In HNSCC, previous attempts have been made to come up with a set of internal control genes using qPCR data ([@ref-16]; [@ref-17]) or using tumors and healthy controls ([@ref-21]). However, it is important that the discovery is made from a transcriptome-wide study that takes into account data from tumors and their matched control samples. This is especially important as we have data on HNSCC from large consortia, like TCGA ([@ref-25]), and data from HNSCC from non-TCGA cohorts ([@ref-15], [@ref-14]). It is not surprising that the genes in our discovery set code for structural proteins (ribosomal, cell structure and integrity) and perform essential functions like glycolysis and translation ([Table S2](#supp-6){ref-type="supplementary-material"}). In the validation study, *RPL30*, *RPL27*, *PSMC5*, *OAZ1*, and *MTCH1* came as the top five ranked genes with stable expression across all the samples. Both *RPL27* and *RPL30* were previously found to be one the most stable candidate internal control genes ([@ref-6]; [@ref-16]) with stable expression in salivary samples of oral cancer patients ([@ref-17]). Additionally, previous findings on non-HNSCC tumors had *RPL27*, *RPL30*, and *MTCH1* in the list of top internal control genes ([@ref-20]). Although, our data supports *PSMC5*, *OAZ1*, and *MTCH1* were stably expressed and ranked after *RPL30* and *RPL27* by RefFinder, they were expressed at a lower level than *RPL30* and *RPL27*. Therefore, we suggest using *RPL30* or *RPL27* in combination with one of the three genes (*PSMC5*, *MTCH1*, and *OAZ1*) to serve as a minimal set of control genes in head and neck tumor gene expression studies.

Our study suffers from some shortcomings. First, our sample size was small. Second, the qPCR studies, although highly sensitive and widely used, could have resulted in a bias in our gene expression data. RNA input volume, cDNA synthesis efficiency, pipetting volumes and accuracy, and primer amplification efficiencies are some of the factors that may affect qPCR results ([@ref-4]). Other factors that might have influenced our selection of the discovery set are inter-platform and -assay variability, temporal, spatial, and experimental conditions (for example, drug treatment), and presence of transcript variants in tumor samples. A larger sample size for different experimental conditions and data from cell lines assayed by using a single kit and a single platform (for example, total transcriptome RNA-seq using a single provider's platform and assay version) may provide answers to these in the future. Third, the selection of genes in our study might have gotten biased as a result of the field effect (due to use of adjacent normal tissues). Use of true normal tissues may circumvent this issue. However, due to the stringency of the ethics committee rules to obtain additional normal tissues from patients without a clinical reason(s), studies with true normal tissues, outside of the adjacent normal, are least likely to take place. Fourth, in our study, like previously reported ([@ref-20]), a difference in the ranking of genes may be tool-specific and certain parameters (like qPCR amplification efficiency) might have influenced the ranking of the genes. A better design and a robust statistical tool to rank genes may overcome this limitation in the future.

Conclusions
===========

Although past studies are heavily reliant on the use of *ACTB*, *TUBB*, and *GAPDH* to normalize expression data, evidence suggests that the expression of these genes vary greatly and are not suitable internal control genes ([@ref-10]; [@ref-18]; [@ref-23]; [@ref-28]). Additionally, expression of internal control genes may vary based on experimental conditions and tumor type. Therefore, we used a larger discovery set to validate internal control genes across HNSCC tumors and their paired normal samples to come up with a set of robust and stably expressed genes (*RPL30*, *RPL27*, *PSMC5*, *MTCH1*, and *OAZ1*) across tissues.
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###### Fig. S1. Representative histological images of the adjacent normal tissues.

###### 

Click here for additional data file.
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###### Fig. S2. Standard curves of 18 candidate housekeeping genes in the discovery set.

The qPCR was performed using 3 times dilution of the template. R^2^ indicates the correlation coefficient and amplification efficiencies on the basis of the slopes.

###### 

Click here for additional data file.
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###### Fig. S3. Dissociation curves for the 18 candidate housekeeping genes in the discovery set.

The single peak of dissociation curve in qPCR performed for all the genes indicates the specific amplification.

###### 

Click here for additional data file.
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###### Fig. S4. Agarose gel electrophoresis of qPCR amplicons.

The labels in bold are the 18 pair of primers used in the final validation process ([Table 1A](#table-1){ref-type="table"}) and other labels are the extra primers (including \*) used during the optimization process.

###### 

Click here for additional data file.
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###### Table S1. A larger set of genes common between the microarray data and RNA-seq data with high expression in both tumor and normal samples.

###### 

Click here for additional data file.
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###### Table S2. Genes selected in the discovery set and their function.

###### 

Click here for additional data file.
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###### Table S3. Raw data on standard curves and Ct value calculation.

###### 

Click here for additional data file.
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HNSCC

:   Head and neck squamous cell carcinoma

NTC

:   No template control

NAC

:   No amplification control

NPC

:   No primer control.
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